The use of semaglutide alongside other antidiabetic agents presents an elevated risk of hyperglycemia and must be performed under close medical guidance [12]
The FDA told Healthcare Brew it doesnt generally comment on specific studies but pointed to two June 15 notices warning telehealth compounders and patients about the risks of illegal manufacturing and promotion of compounded drugs
Immediate steps to improve therapeutic outcomes with GLP1R agonists Our results underscore the value of including female subjects in pre-clinical studies, such that sex differences in efficacy or tolerability can be assessed at early stages of the development pipeline
If finalized, this means 503B outsourcing facilities - which compound drugs in larger batches for healthcare facilities and telehealth platforms - would lose the legal basis to compound these specific GLP-1 medications at scale
Your health deserves more than a trend
A: Semaglutide is taken via subcutaneous injection, which means it's injected under the skin, usually once a week